Overexpression of Survivin‑1, TAG‑72 and HERC5 in patients diagnosed with hepatocellular carcinoma in the Black Sea coast geographical area

Suceveanu,Andra-Iulia; Micu,Ioan Sergiu; Baltatescu,Gabriela-Izabela; Petcu,Lucian Cristian; Dobrin,Nicolae; Brinzan,Costel; Nitipir,Cornelia; Mazilu,Laura; Botea,Florin; Herlea,Vlad; Voinea,Felix; Suceveanu,Adrian Paul

doi:10.3892/etm.2021.9715

Overexpression of Survivin‑1, TAG‑72 and HERC5 in patients diagnosed with hepatocellular carcinoma in the Black Sea coast geographical area

Authors:
- Andra-Iulia Suceveanu
- Ioan Sergiu Micu
- Gabriela-Izabela Baltatescu
- Lucian Cristian Petcu
- Nicolae Dobrin
- Costel Brinzan
- Cornelia Nitipir
- Laura Mazilu
- Florin Botea
- Vlad Herlea
- Felix Voinea
- Adrian Paul Suceveanu
View Affiliations

Affiliations: Department of Gastroenterology, ‘Ovidius’ University, 900527 Constanta, Romania, Research and Development Centre for The Morphologic and Genetic Study of Malignant Pathology, ‘Ovidius’ University, 900527 Constanta, Romania, Dentistry Faculty, Biophysics and Biostatistics Disciplines, ‘Ovidius’ University, 900527 Constanta, Romania, Doctoral School of Medicine, ‘Ovidius’ University, 900527 Constanta, Romania, Department of Oncology, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania, Department of Oncology, ‘Ovidius’ University, 900527 Constanta, Romania, Liver Transplant and General Surgery Centre, ‘Fundeni’ Institute, 022328 Bucharest, Romania, Department of Pathology, ‘Fundeni’ Institute, 022328 Bucharest, Romania, Department of Urology, ‘Ovidius’ University, 900527 Constanta, Romania
Published online on: January 26, 2021 https://doi.org/10.3892/etm.2021.9715
Article Number: 284

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epidemiological data regarding hepatocellular carcinoma (HCC) report unsatisfactory morbimortality rates despite the global efforts to decrease the incidence and prolong patient survival. Current guidelines lack diagnostic biomarkers to better characterize patients with HCC. We aimed to validate the overexpression of Survivin‑1, tumor‑associated glyocoprotein 72 (Tag‑72), and HECT and RLD domain containing E3 ubiquitin protein ligase 5 (HERC5) as tissue biomarkers for HCC characterization in patients from our geographical area and to standardize a local biomarker panel to be introduced in the current management guideline. Thirty samples of histologically confirmed HCC were compared to an equal number of samples of benign tumors in terms of Survivin‑1, TAG‑72, and HERC5 overexpression. Student's t‑test, Mann‑Whitney U test and Chi‑square test were used to find differences between the two studied groups and to compare the categorical variables. The discriminative power of Survivin‑1, Tag‑72, and HERC5 overexpression was assessed using ROC curves. The multivariate linear regression analysis revealed that Survivin, Tag‑72, and HERC5 were significantly overexpressed in older male patients, with α‑fetoprotein (AFP) >200 ng/dl, low serum albumin, as well as in patients with imaging features of portal thrombosis and ascites. The diagnostic performance of Survivin‑1, Tag‑72 and HERC5 tissue biomarkers for HCC characterization was superior to that of the gold‑standard AFP. Our study results validate the overexpression of Survivin‑1, Tag‑72, and HERC5 as tissue biomarkers for HCC characterization in patients from our geographical region and could be standardized in the current HCC management guideline.

View Figures

View References

1	Baecker A, Liu X, La Vecchia C and Zhang ZF: Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. Eur J Cancer Prev. 27:205–212. 2018.PubMed/NCBI View Article : Google Scholar
2	Liang Y, Chen J, Yu Q, Ji T, Zhang B, Xu J, Dai Y, Xie Y, Lin H, Liang X and Cai X: Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma. Cancer Med. 6:2787–2795. 2017.PubMed/NCBI View Article : Google Scholar
3	Kudo M: Systemic Therapy for hepatocellular carcinoma: 2017 Update. Oncology. 93 (Suppl 1):S135–S146. 2017.PubMed/NCBI View Article : Google Scholar
4	Kudo M: Immuno-oncology in hepatocellular carcinoma: 2017 Update. Oncology. 93 (Suppl 1):S147–S159. 2017.PubMed/NCBI View Article : Google Scholar
5	Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnù L, et al: Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: Both or neither? Am J Gastroenterol. 101:524–532. 2006.PubMed/NCBI View Article : Google Scholar
6	Nishimoto S, Fukuda D, Higashikuni Y, Tanaka K, Hirata Y, Murata C, Kim-Kaneyama JR, Sato F, Bando M, Yagi S, et al: Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance. Sci Adv. 2(e1501332)2016.PubMed/NCBI View Article : Google Scholar
7	El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 142:1264–1273.e1. 2012.PubMed/NCBI View Article : Google Scholar
8	Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH, Liu CJ, Chen PJ, You SL, Wang LY, Chen WJ and Chen CJ: Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: Long-term predictors from a community-based cohort study. J Clin Oncol. 28:4587–4593. 2010.PubMed/NCBI View Article : Google Scholar
9	Jee SH, Ohrr H, Sull JW and Samet JM: Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea. J Natl Cancer Inst. 96:1851–1856. 2004.PubMed/NCBI View Article : Google Scholar
10	Kannangai R, Wang J, Liu QZ, Sahin F and Torbenson M: Survivin-1 overexpression in hepatocellular carcinoma is associated with p53 dysregulation. Int J Gastrointest Cancer. 35:53–60. 2005.PubMed/NCBI View Article : Google Scholar
11	Jin B, Wang X, Jin Y, Xia W, Chen B, Liu L, Chen Z, Hong L, Du W, Yan K, et al: Detection of serum gastric cancer-associated MG7-Ag from gastric cancer patients using a sensitive and convenient ELISA method. Cancer Invest. 27:227–233. 2009.PubMed/NCBI View Article : Google Scholar
12	Chauhan SC, Vinayek N, Maher DM, Bell MC, Dunham KA, Koch MD, Lio Y and Jaggi M: Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: Antigens for multi-targeted antibody-guided therapy. J Histochem Cytochem. 55:867–875. 2007.PubMed/NCBI View Article : Google Scholar
13	Xue F, Higgs BW, Huang J, Morehouse C, Zhu W, Yao X, Brohawn P, Xiao Z, Sebastian Y, Liu Z, et al: HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma. J Transl Med. 13(379)2015.PubMed/NCBI View Article : Google Scholar
14	Bernassola F, Karin M, Ciechanover A and Melino G: The HECT family of E3 ubiquitin ligases: Multiple players in cancer development. Cancer Cell. 14:10–21. 2008.PubMed/NCBI View Article : Google Scholar
15	Torbenson MS, Ng IOL, Park YN, Roncalli M and Sakamoto M: Hepatocellular Carcinoma. In: WHO Classification of Tumours Editorial Board. Digestive system tumours. 5th edition. International Agency for Research on Cancer, Lyon, pp229-239, 2019.
16	Ramos-Vara JA and Miller MA: When tissue antigens and antibodies get along: Revisiting the technical aspects of immunohistochemistry-the red, brown, and blue technique. Vet Pathol. 51:42–87. 2014.PubMed/NCBI View Article : Google Scholar
17	Torlakovic EE, Cheung CC, D'Arrigo C, Dietel M, Francis GD, Gilks CB, Hall JA, Hornick JL, Ibrahim M, Marchetti A, et al: Evolution of quality assurance for clinical immunohistochemistry in the era of precision medicine-part 2: Immunohistochemistry test performance characteristics. Appl Immunohistochem Mol Morphol. 25:79–85. 2017.PubMed/NCBI View Article : Google Scholar
18	Bolocan A, Păduraru DN, Nițipir C, Hainăroșie R, Pițuru SM, Diaconu C, Suceveanu A and Stoian CD: Mixed adenoneuroendocrine carcinoma of the gastrointestinal tract-features, diagnosis, management and prognosis. Rom Biotechnol Lett. 23:14193–14202. 2018.PubMed/NCBI View Article : Google Scholar
19	Gurtsevitch VE: Human oncogenic viruses: Hepatitis B and hepatitis C viruses and their role in hepatocarcinogenesis. Biochemistry (Mosc). 73:504–513. 2008.PubMed/NCBI View Article : Google Scholar
20	Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C, et al: Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 155:323–331. 2002.PubMed/NCBI View Article : Google Scholar
21	Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA, et al: World gastroenterology organisation guideline. Hepatocellular carcinoma (HCC): A global perspective. J Gastrointestin Liver Dis. 19:311–317. 2010.PubMed/NCBI
22	Suceveanu AI, Pantea Stoian A, Mazilu L, Voinea F, Hainăroșie R, Diaconu CC, Pițuru S, Nițipir C, Badiu DC, Ceaușu I and Suceveanu AP: Interferon-free therapy is not a trigger for hepatocellular carcinoma in patients with chronic infection with hepatitis C virus. Farmacia. 66:904–908. 2018.PubMed/NCBI View Article : Google Scholar
23	Carr BI, Akkiz H, Üsküdar O, Yalçın K, Guerra V, Kuran S, Karaoğullarından Ü, Altıntaş E, Özakyol A, Tokmak S, et al: HCC with low- and normal-serum alpha-fetoprotein levels. Clin Pract (Lond). 15:453–464. 2018.PubMed/NCBI View Article : Google Scholar
24	Yang SL, Liu LP, Yang S, Liu L, Ren JW, Fang X, Chen GG and Lai PB: Preoperative serum α-fetoprotein and prognosis after hepatectomy for hepatocellular carcinoma. Br J Surg. 103:716–724. 2016.PubMed/NCBI View Article : Google Scholar
25	An SL, Xiao T, Wang LM, Rong WQ, Wu F, Feng L, Liu FQ, Tian F and Wu JX: Prognostic significance of preoperative serum alpha-fetoprotein in hepatocellular carcinoma and correlation with clinicopathological factors: A single-center experience from China. Asian Pac J Cancer Prev. 16:4421–4427. 2015.PubMed/NCBI View Article : Google Scholar
26	Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, et al: Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update. Hepatol Int. 11:317–370. 2017.PubMed/NCBI View Article : Google Scholar
27	Ardeleanu V, Georgescu C, Frîncu LD, Frâncu LL and Vesa D: Angiogenesis as prospective molecular biology technique for cancer study. Rom Biotehnol Lett. 19:9637–9648. 2014.
28	Ardeleanu V, Francu L and Georgescu C: Neoangiogenesis. Assessment in esophageal adenocarcinomas. Indian J Surg. 77 (Suppl 3):S971–S976. 2015.PubMed/NCBI View Article : Google Scholar